Kishor Bhatia
Net worth: - $ as of 31/08/2026
Net worth: - $ as of 31/08/2026
Kishor G.
Bhatia currently works at Lantern Pharma, Inc., as Chief Scientific Officer from 2019.
Dr. Bhatia also formerly worked at National Cancer Institute, as Director-AIDS Malignancy Program from 2007 to 2016 and Georgetown University, as Research Assistant Professor from 1985 to 1989.
Dr. Bhatia received his doctorate degree from the University of Mumbai and undergraduate degree from the University of Pune.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LANTERN PHARMA, INC. -.--% | 17/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| LANTERN PHARMA INC. | Chief Tech/Sci/R&D Officer | 01/12/2019 |
| Companies | Position | End |
|---|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Corporate Officer/Principal | 01/07/2016 |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1989 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of Mumbai
University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
University of Pune
University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
Select your edition
All financial news and data tailored to specific country editions